Alaa S Tulbah1,2, Elvira Pisano3, Santo Scalia3, Paul M Young1,4, Daniela Traini1,4, Hui Xin Ong1,4. 1. Respiratory Technology, Woolcock Institute of Medical Research & Discipline of Pharmacology, Sydney Medical School, Sydney University, NSW 2037, Australia. 2. Faculty of Pharmacy, Umm Al Qura University, Makkah, Saudi Arabia. 3. Department of Chemical & Pharmaceutical Sciences, University of Ferrara, Italy. 4. Woolcock Emphysema Centre, Woolcock Institute of Medical Research, Glebe, NSW 2037, Australia.
Abstract
AIM: Current inhaled treatments are not adequate to treat all lung diseases. In this study, a promising nanotechnology has been developed to deliver a potential anti-inflammatory and muco-inhibitory compound, simvastatin, for treatment of inflammatory lung diseases via inhalation. MATERIALS & METHODS: Simvastatin nanoparticles (SV-NPs) encapsulated with poly(lactic-co-glycolic) acid were fabricated using the solvent and anti-solvent precipitation method. RESULTS: SV-NPs were found to be stable up to 9 months at 4°C in a freeze-dried form prior to reconstitution. The amount of mucus produced was significantly reduced after SV-NPs treatment on inflammation epithelial cell models and were effective in suppressing the proinflammatory marker expression. CONCLUSION: This study suggests that SV-NPs nebulization could potentially be used for the treatment of chronic pulmonary diseases.
AIM: Current inhaled treatments are not adequate to treat all lung diseases. In this study, a promising nanotechnology has been developed to deliver a potential anti-inflammatory and muco-inhibitory compound, simvastatin, for treatment of inflammatory lung diseases via inhalation. MATERIALS & METHODS:Simvastatin nanoparticles (SV-NPs) encapsulated with poly(lactic-co-glycolic) acid were fabricated using the solvent and anti-solvent precipitation method. RESULTS: SV-NPs were found to be stable up to 9 months at 4°C in a freeze-dried form prior to reconstitution. The amount of mucus produced was significantly reduced after SV-NPs treatment on inflammation epithelial cell models and were effective in suppressing the proinflammatory marker expression. CONCLUSION: This study suggests that SV-NPs nebulization could potentially be used for the treatment of chronic pulmonary diseases.